Business Description
Galmed Pharmaceuticals Ltd
NAICS : 325412
SIC : 2834
ISIN : IL0011313900
Description
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 418.05 | |||||
| Equity-to-Asset | 0.88 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Piotroski F-Score | 4/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 49.8 | |||||
| 3-Year EPS without NRI Growth Rate | 49.9 | |||||
| 3-Year FCF Growth Rate | 50.8 | |||||
| 3-Year Book Growth Rate | -55.4 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 64.97 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 9-Day RSI | 41.33 | |||||
| 14-Day RSI | 43.55 | |||||
| 6-1 Month Momentum % | -19.15 | |||||
| 12-1 Month Momentum % | -29.63 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 7.03 | |||||
| Quick Ratio | 7.03 | |||||
| Cash Ratio | 6.82 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -52.5 | |||||
| Shareholder Yield % | 3.45 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -43.67 | |||||
| ROA % | -38.06 | |||||
| ROIC % | -195.97 | |||||
| ROC (Joel Greenblatt) % | -4523.33 | |||||
| ROCE % | -46.85 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.25 | |||||
| Price-to-Tangible-Book | 0.25 | |||||
| EV-to-EBIT | 1.12 | |||||
| EV-to-EBITDA | 1.13 | |||||
| EV-to-FCF | 1.58 | |||||
| Price-to-Net-Current-Asset-Value | 0.3 | |||||
| Price-to-Net-Cash | 0.31 | |||||
| Earnings Yield (Greenblatt) % | 89.29 | |||||
| FCF Yield % | -95.47 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Galmed Pharmaceuticals Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -33.919 | ||
| Beta | 1.64 | ||
| Volatility % | 53.62 | ||
| 14-Day RSI | 43.55 | ||
| 14-Day ATR (€) | 0.00068 | ||
| 20-Day SMA (€) | 2.736 | ||
| 12-1 Month Momentum % | -29.63 | ||
| 52-Week Range (€) | 2.736 - 5.496 | ||
| Shares Outstanding (Mil) | 1.66 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Galmed Pharmaceuticals Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Galmed Pharmaceuticals Ltd Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Galmed Pharmaceuticals Ltd Frequently Asked Questions
What is Galmed Pharmaceuticals Ltd(FRA:GPH)'s stock price today?
The current price of FRA:GPH is €2.74. The 52 week high of FRA:GPH is €5.50 and 52 week low is €2.74.
When is next earnings date of Galmed Pharmaceuticals Ltd(FRA:GPH)?
The next earnings date of Galmed Pharmaceuticals Ltd(FRA:GPH) is 2024-12-31 Est..
Does Galmed Pharmaceuticals Ltd(FRA:GPH) pay dividends? If so, how much?
Galmed Pharmaceuticals Ltd(FRA:GPH) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers